• Cryptocurrencies
  • Prediction Markets
  • News
  • Agentic Trading
  • Blog
  • Leagues

Search Cryptocurrencies

Trending Cryptocurrencies

CoinRithm

Company

Legal Entity
Bees-x Limited
Company Number
13308136
Incorporated In
England and Wales
Registered Office
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is an information and research service operated by Bees-x Limited. It is not authorised by the Financial Conduct Authority (FCA) to carry on regulated activities, and nothing on this site is financial advice.

Explore

CryptocurrenciesPrediction MarketsNewsBlogAgent ArenaLeagues

Features

DashboardMock TradeAgentic TradingPortfolioWatchlistSettings

Company

About UsMethodologyFor ClassroomsTerms of UsePrivacy PolicyCookie PolicyDisclaimer

Support

Contact SupportFAQDeveloper kitMCP docs

Socials

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. All rights reserved.
Get it on Google PlayDownload on the App Store
  • Home
  • MarketsPrediction Markets
  • News
  • Dashboard
  1. Prediction Markets
  2. Regulation
  3. FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

RegulationOne-OffHealth & Medicine6mo
KalshiKalshiCheck availabilityKYC required2% fee
Current implied probability
Yes
Yes 0%
Market quality

24 / 100

Low quality
24h Volume

$0

Liquidity

$0

Low liquidity
Bid / Ask

63.0% / 79.0%

Spread

25.4%

Wide spread
Market data

Updated 7 minutes ago

Jun 17, 26, 9:30 PMJan 1, 27, 4:59 AM

Trends

Outcome24hChance
Yes
Yes
0%
No
No
100%

Selected outcome

Yes0%

Rules

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
  • Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
  • In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.

Related Markets

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

$1.1K
Yes: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

$425
2026: 33%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will estradiol be available over-the-counter in the US before 2030?

$350
Yes: 8.2%Manifold MarketsMANIFOLD MARKETS
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

$0
Yes: 0%KalshiKALSHI
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

$44.1K
Yes: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

$6K
Yes: 11%PolymarketPOLYMARKET

Active in these topics

BitcoinBTC$64,447.67-1.85%EthereumETH$1,747.51-2.52%SolanaSOL$72.03-2.16%DogecoinDOGE$0.0861-1.12%XRPXRP$1.19-2.52%BNBBNB$601.10-0.62%

Related News

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain ReporterCLARITY Act faces ethics showdown as David Nage eyes July voteCrypto NewsBinance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain ReporterSolana Institute warns Senate against weakening CLARITY ActCrypto NewsSummer of crypto (regs): State of Crypto CoindeskPhilippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Rules

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
  • Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
  • In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.